Beam Therapeutics Inc. Common Stock (BEAM) Stock Price
BEAMStock
$29.32+74.01%52W
Market Cap$3.03B
P/E—
PEG Ratio—
Div yield—
Beta2.20
BEAM Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-21.13%
Price vs S&P 500 (4W)11.62%
VGM Score54.94
BEAM Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.13 | -$1.18 | -4.80%(-$0.05) | |
| Q1 2026 | -$1.01 | -$0.91 | +10.06%(+$0.10) | |
| Q4 2025 | -$1.12 | $2.33 | +308.96%(+$3.45) | |
| Q3 2025 | -$1.01 | -$1.10 | -8.95%(-$0.09) | |
| Q2 2025 | -$1.09 | -$1.00 | +8.36%(+$0.09) |
BEAM Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.32
4.32
4.32
4.26
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BEAMBeam Therapeutics Inc. Common Stock | C | B | B | $29.32 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
About Beam Therapeutics Inc. Common Stock
Beam Therapeutics is a precision genetic medicine company leveraging proprietary base editing technology to develop lifelong cures for serious diseases. The company's pipeline focuses on hematologic and genetic disorders, with lead programs including BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency. Operations are based in the United States.